The Journal of Heart and Lung Transplantation
Volume 29, Issue 3 , Pages 299-305 , March 2010

Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy

Presented in part as a poster at the meeting of Swiss Society of Infectious Diseases and Immunocompromised Host Society, Crans-Montana, Switzerland, July 2006.

  • Ilker Uçkay, MD

      Affiliations

    • Service of Infectious Diseases, University of Geneva, Geneva, Switzerland
    • ,
  • Paola M. Gasche-Soccal, MD

      Affiliations

    • Service of Pulmonary Medicine, University of Geneva, Geneva, Switzerland
    • Clinic of Thoracic Surgery, University of Geneva, Geneva, Switzerland
    • ,
  • Laurent Kaiser, MD

      Affiliations

    • Service of Infectious Diseases, University of Geneva, Geneva, Switzerland
    • ,
  • Richard Stern, MD

      Affiliations

    • Orthopaedic Surgery Service, University of Geneva, Geneva, Switzerland
    • ,
  • Jesica Mazza-Stalder, MD

      Affiliations

    • Service of Pulmonary Medicine, University of Geneva, Geneva, Switzerland
    • Service of Pulmonary Medicine, University Hospital of Vaud, Lausanne, Switzerland
    • ,
  • John-David Aubert, MD

      Affiliations

    • Service of Pulmonary Medicine, University Hospital of Vaud, Lausanne, Switzerland
    • ,
  • Christian van Delden, MD

      Affiliations

    • Service of Infectious Diseases, University of Geneva, Geneva, Switzerland
    • Service of Transplantation, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland
    • Corresponding Author InformationReprint requests: Christian van Delden, MD, Service of Transplantation, Department of Surgery, Hôpitaux Universitaire de Genève, 24 Rue Micheli-du-Crest, CH-1211 Geneva 14, Switzerland. Telephone: ++41-22-372-32-07. Fax: ++41-22-372-98-30

References 

  1. Milstone AP, Brumble LM, Barnes J, et al. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J. 2006;28:131–137
  2. Wendt CH. Community respiratory viruses: organ transplant recipients. Am J Med. 1997;102:31–36
  3. Chakinala MM, Walter MJ. Community acquired respiratory viral infections after lung transplantation: clinical features and long-term consequences. Semin Thorac Cardiovasc Surg. 2004;16:342–349
  4. Community-acquired respiratory viruses. Am J Transplant. 2004;4:105–109
  5. McCurdy LH, Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant. 2003;22:745–753
  6. Palmer SM, Henshaw NG, Howell DN, et al. Community respiratory viral infection in adult lung transplant recipients. Chest. 1998;113:944–950
  7. Glanville AR, Scott AI, Morton JM, et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2005;24:2114–2119
  8. Peck AJ, Englund JA, Kuypers J, et al. Respiratory virus infection among hematopoietic cell transplantation recipients: evidence for asymptomatic parainfluenza virus infection. Blood. 2007;110:1681–1688
  9. Boeckh M, Englund J, Li Y, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis. 2007;44:245–249
  10. Adams RH. Preemptive treatment of pediatric bone marrow transplant patients with asymptomatic respiratory syncytial virus infection with aerosolized ribavirin. Biol Blood Marrow Transplant. 2001;7:16–18
  11. Ljungman P, Ward KN, Crooks BN, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2001;28:479–484
  12. Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996;22:778–782
  13. Englund JA, Whimbey EE. Community-acquired respiratory viruses after hemopoietic stem cell or solid organ transplantation. In:  Bowden RA,  Ljungman P,  Paya CV editor. Transplant infections. 2nd ed.. Philadelphia: Lippincott, Williams and Wilkins; 2003;p. 375–398
  14. Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant. 2000;25:751–755
  15. Van Kraaij MG, van Elden LJ, van Loon AM, et al. Frequent detection of respiratory viruses in adult recipients of stem cell transplants with the use of real-time polymerase chain reaction, compared with viral culture. Clin Infect Dis. 2005;40:662–669
  16. Cortez K, Murphy BR, Almeida KN, et al. Immune-globulin prophylaxis of respiratory syncytial virus infection in patients undergoing stem-cell transplantation. J Infect Dis. 2002;186:834–83815
  17. Chakrabarti S, Collingham KE, Holder K, et al. Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant. 2001;28:759–763
  18. Krinzman S, Basşgöz N, Kradin R, et al. Respiratory syncytial virus-associated infections in adult recipients of solid organ transplants. J Heart Lung Transplant. 1998;17:202–210
  19. Swedish Consensus Group. Management of infections caused by respiratory syncytial virus. Scand J Infect Dis. 2001;33:323–328
  20. Hirsch H, Widmer A, Francioli P. Respiratorisches Syncytial-Virus (RSV) Infektion: Massnahmen beim immunsupprimierten Patienten. Swiss-NOSO Bulletin. 2004;11:17–21
  21. Garbino J, Gerbase MW, Wunderli W, et al. Lower respiratory viral illnesses: improved diagnosis by molecular methods and clinical impact. Am J Respir Crit Care Med. 2004;170:1197–1203
  22. Garbino J, Crespo S, Aubert JD, et al. A prospective hospital-based study of the clinical impact of non-severe acute respiratory syndrome (non-SARS)-related human coronavirus infection. Clin Infect Dis. 2006;43:1009–1015
  23. Weinberg A, Zamora MR, Li S, et al. The value of polymerase chain reaction for the diagnosis of viral respiratory tract infections in lung transplant recipients. J Clin Virol. 2002;25:171–175
  24. Dewhurst-Maridor G, Simonet V, Bornand JE, et al. Development of a quantitative TaqMan RT-PCR for respiratory syncytial virus. J Virol Methods. 2004;120:41–49
  25. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection. J Heart Lung Transplant. 1996;15:1–15
  26. Ko JP, Shepard JA, Sproule MW, et al. CT manifestations of respiratory syncytial virus infection in lung transplant recipients. J Comput Assist Tomogr. 2000;24:235–241
  27. Matar LD, McAdams HP, Palmer SM, et al. Respiratory viral infections in lung transplant recipients: radiologic findings with clinical correlation. Radiology. 1999;213:735–742
  28. Holt ND, Gould FK, Taylor CE, et al. Incidence and significance of noncytomegalovirus viral respiratory infection after adult lung transplantation. J Heart Lung Transplant. 1997;16:416–419
  29. Khalifah AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med. 2004;170:181–187
  30. Billings JL, Hertz MI, Savik K, et al. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant. 2002;21:559–566
  31. Tcheurekdjian H, Martin J, Kobayashi R, et al. Intrainfusion and postinfusion adverse events related to intravenous immunoglobulin therapy in immunodeficiency states. Allergy Asthma Proc. 2006;27:532–536
  32. Aghamohammadi A, Farhoudi A, Nikzad M, et al. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency. Ann Allergy Asthma Immunol. 2004;92:60–64
  33. Janai HK, Marks MI, Zaleska M, et al. Ribavirin: adverse drug reactions, 1986 to 1988. Pediatr Infect Dis J. 1990;9:209–211
  34. Boeckh M, Berrey MM, Bowden RA, et al. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis. 2001;184:350–354
  35. Kusuda S, Koizumi T, Sakai T, et al. Results of clinical surveillance during the Japanese first palivizumab season in 2002–2003. Pediatr Int. 2006;48:362–368
  36. Knowles SR, Phillips EJ, Dresser L, et al. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin Infect Dis. 2003;37:1139–1142
  37. Pelaez A, Lyon GM, Force SD, et al. Efficacy of oral ribavirin in lung transplant recipients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant. 2009;28:67–71
  38. Lofland JH, O'Connor JP, Chatterton ML, et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Ther. 2000;22:1357–1369
  39. Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics. 2007;25:55–71
  40. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112:1442–1446
  41. Pohl C, Green M, Wald ER, et al. Respiratory syncytial virus infections in pediatric liver transplant recipients. J Infect Dis. 1992;165:166–169
  42. Englund JA, Piedra PA, Whimbey E. Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. Am J Med. 1997;102:61–70
  43. Allen MD, Burke CM, McGregor CG, et al. Steroid-responsive bronchiolitis after human heart–lung transplantation. J Thorac Cardiovasc Surg. 1986;92:449–451
  44. Doud JR, Hinkamp T, Garrity ER. Respiratory syncytial virus pneumonia in a lung transplant recipient. J Heart Lung Transplant. 1992;11:77–79
  45. Murris-Espin M, Didier A, Carre P, et al. Continuous aerosolised ribavirin for respiratory syncytial virus infection in lung transplant recipients. Lancet. 1993;341:897
  46. Wendt CH, Fox JM, Hertz MI. Paramyxovirus infection in lung transplant recipients. J Heart Lung Transplant. 1995;14:479–485

PII: S1053-2498(09)00639-1

doi: 10.1016/j.healun.2009.08.012

The Journal of Heart and Lung Transplantation
Volume 29, Issue 3 , Pages 299-305 , March 2010

Article Tools